In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

Sarepta Therapeutics Inc. has signed a licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. to obtain exclusive global rights to multiple clinical, preclinical and discovery-stage ...

In the largest collaboration of 2024, Sarepta Therapeutics Inc. and Arrowhead Pharmaceuticals Inc. entered a sprawling global licensing deal that includes a swath of clinical and preclinical ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers ...

and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave TM platform to provide a sustainable source of best- or first-in-class candidates. Nxera ...

Barclays raised the firm’s price target on Sarepta (SRPT) to $209 from $203 and keeps an Overweight rating on the shares. The company reported a big Q3 beat on both total and Elevidys revenue ...

Cantor Fitzgerald analyst Kristen Kluska upgraded Sarepta (SRPT) to Overweight from Neutral with a price target of $167, up from $152. The company reported Q3 earnings, the first full quarter ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. My colleagues have gathered ...

(RTTNews) - Below are the earnings highlights for Sarepta Therapeutics (SRPT): Earnings: $33.6 million in Q3 vs. -$40.9 million in the same period last year. EPS: $0.34 in Q3 vs. -$0.46 in the ...